- Home
- AMPY vs PBYI Comparison
AMPY vs PBYI Comparison
Compare AMPY & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMPY
- PBYI
- Stock Information
- Founded
- AMPY 2011
- PBYI 2010
- Country
- AMPY United States
- PBYI United States
- Employees
- AMPY N/A
- PBYI N/A
- Industry
- AMPY Oil & Gas Production
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- AMPY Energy
- PBYI Health Care
- Exchange
- AMPY Nasdaq
- PBYI Nasdaq
- Market Cap
- AMPY 160.2M
- PBYI 171.7M
- IPO Year
- AMPY 2011
- PBYI N/A
- Fundamental
- Price
- AMPY $4.49
- PBYI $4.52
- Analyst Decision
- AMPY Strong Buy
- PBYI Strong Buy
- Analyst Count
- AMPY 1
- PBYI 1
- Target Price
- AMPY $11.00
- PBYI $7.00
- AVG Volume (30 Days)
- AMPY 399.2K
- PBYI 525.6K
- Earning Date
- AMPY 11-05-2025
- PBYI 11-06-2025
- Dividend Yield
- AMPY N/A
- PBYI N/A
- EPS Growth
- AMPY N/A
- PBYI 434.29
- EPS
- AMPY 0.38
- PBYI 0.97
- Revenue
- AMPY $279,289,100.00
- PBYI $238,062,000.00
- Revenue This Year
- AMPY $2.33
- PBYI N/A
- Revenue Next Year
- AMPY N/A
- PBYI N/A
- P/E Ratio
- AMPY $11.70
- PBYI $4.64
- Revenue Growth
- AMPY N/A
- PBYI 8.63
- 52 Week Low
- AMPY $2.27
- PBYI $2.32
- 52 Week High
- AMPY $7.35
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- AMPY 67.30
- PBYI 47.80
- Support Level
- AMPY $3.91
- PBYI $4.30
- Resistance Level
- AMPY $4.09
- PBYI $4.72
- Average True Range (ATR)
- AMPY 0.20
- PBYI 0.26
- MACD
- AMPY 0.04
- PBYI -0.10
- Stochastic Oscillator
- AMPY 99.35
- PBYI 19.30
About AMPY Amplify Energy Corp.
Amplify Energy Corp is an independent oil and natural gas company engaged in the acquisition, development, exploitation, and production of oil and natural gas properties in the United States. The company's oil and natural gas properties are located in large, mature oil and natural gas reservoirs. The company assets consists of producing oil and natural gas properties located in Oklahoma, the Rockies, federal waters offshore Southern California, East Texas/North Louisiana and Eagle Ford.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.